Drug intelligence / Profile preview

Hexyon

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Hexyon is a fully liquid, ready-to-use, hexavalent vaccine composed of six antigens: diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), hepatitis B surface antigen (HBsAg, produced using recombinant DNA technology in Hansenula polymorpha yeast), inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein. It is indicated for primary and booster vaccination of infants and toddlers aged from six weeks to 24 months against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Hib disease[1][2][3][4][5][7][9]. The vaccine works by inducing the immune system to produce antibodies to these pathogens, providing active immunity. Its formulation is fully liquid, requiring no reconstitution, designed to reduce handling errors, improve convenience, and increase compliance[2][3][4][6]. Hexyon's immunogenicity and safety profile are comparable to other hexavalent vaccines, but it has the advantage of a streamlined administration[7].

Brand names
HexyonHexacimaHexaxim
Other names
DTaP-IPV-HepB-Hib
02

Targets

PRNP (Cellular Prion Protein)FHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)Diphtheria toxin

Beyond the preview

Go deeper on Hexyon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexyon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call